PD-L1 anticorps (FITC)

N° du produit ABIN7670211

Cet anticorps Souris Monoclonal détecte spécifiquement PD-L1 dans FACS. Il présente une réactivité envers Humain.

Aperçu rapide pour PD-L1 anticorps (FITC) (ABIN7670211)

Antigène: PD-L1 (CD274 (PD-L1))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp PD-L1 est conjugé à/à la FITC

Application: Flow Cytometry (FACS)

Clone: 9F7

Détail du produit anti-PD-L1 anticorps (FITC)

Fonction: FITC Anti-Human CD274/PD-L1 Antibody[9F7]

Isotype: IgG2a, kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 5 μL/tests

Buffer: Phosphate buffered solution, pH 7.2, containing 0.09 % stabilizer and 1 % protein protectant.

Conseil sur la manipulation: Please protected from prolonged exposure to light and do not freeze.

Stock: 4 °C

Stockage commentaire: This product can be stored at 2-8°C for 12 months.

Date de péremption: 12 months

Détails sur PD-L1

Antigène: PD-L1 (CD274 (PD-L1))

Autre désignation: CD274

Sujet: B7-H1,PD-L1,Programmed cell death ligand 1,B7 homolog 1,B7-H,B7H1,PDL1,PDCD1L1,PDCD1LG1,CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints